Immuno-therapy For Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

What is an immuno-therapy?

Immuno-therapies are a relatively recent development that are sometimes used in the treatment of cancer. They may work by attacking the cancer cells directly, or by activating a patient’s own immune system to mount an effective attack against the cancer.


The TUMOR INFILTRATING LYMPHOCYTE (TIL) therapy being studied in this trial is an investigational immunotherapy named LN-145.

TIL are derived from a patient’s own immune cells called lymphocytes, and specifically T lymphocytes that can recognize and potentially kill the patient’s own cancer cells. Some of these cells naturally travel to, and penetrate existing cancerous tumors, and are then referred to as TUMOR INFILTRATING LYMPHOCYTES (TIL). However, for various reasons the immune-suppressive environment of the cancerous tumors limits their number and activity which diminishes their ability to effectively attack the cancer.

The TIL therapy under investigation in this clinical trial (LN-145) is derived through isolation of a patient’s own naturally occurring TIL from a sample of cancerous tumor removed from the patient. After TIL are extracted from the tumor, they are multiplied in a laboratory until billions of TIL are obtained. Prior to receipt of TIL, patients receive a pre-conditioning therapy to reduce the immune suppressive environment of cancer that remains in the patient. The expanded TIL are then administered via intravenous infusion back to the patient as LN-145 (TIL therapy), with the intention that the TIL will target and infiltrate cancer in the patient and attack the cancer in greater number. Patients receive up to 6 doses of interleukin 2 (IL-2) immediately following TIL infusion to support growth and activation of the TIL in the patient, and to augment the anti-cancer activity of the TIL therapy.


  1. Tumor is surgically isolated from patient.
  2. Tumor sample is shipped to the GMP facility where TIL are isolated and multiplied to generate billions of TIL over three weeks.
  3. Patient initiates a week of pre-conditioning therapy to prepare to receive TIL.
  4. TIL product is administered as a one-time therapy followed by up to 6 doses of IL-2 to support growth and activation of the TIL therapy inside the patient.

TIL Therapy has been Studied in Patients Since 1988


TIL therapy is based on an adoptive cell therapy regimen that was developed at the National Cancer Institute (NCI) and which is currently being applied at a small selection of leading cancer centers around the world.  So far, most of the data on TIL therapy has been obtained from studies in metastatic melanoma, a form of aggressive skin cancer, as well as cervical cancer.

Recent data from two trials at the NCI in patients with metastatic melanoma confirmed TIL treatment was associated with high, durable objective responses.  In a 93 patient Phase 2 trial, the objective response rate (ORR) was 56%.1  Another trial of 101 patients observed complete responses (CR, total elimination of detectable tumors) in 24% of patients, some of whom were free of disease for more than four years. 2

Data from multiple trials in NSCLC show a positive association between the presence of TIL in NSCLC tumors and patient outcomes. 3-10


IOV-LUN-201 is a Phase 2 clinical trial, enrolling patients that have been diagnosed with Stage III or IV NSCLC and have received at least one prior treatment with systemic therapy in the locally advanced or metastatic setting, excluding prior anti-PD-1 or anti-CTLA-4 immunotherapies.

The clinical trial is designed to determine if Iovance investigational TIL therapy (LN-145) is safe and effective for the treatment of metastatic NSCLC (helps patients live longer and/or slow down cancer progression) when administered either alone or in combination with durvalumab.

There are several objectives to the trial, some of which aim to determine:

  • Whether LN-145 alone or in combination with durvalumab reduces or slows the progression of the NSCLC.
  • Whether LN-145 alone or in combination with durvalumab is safe.
  • Whether LN-145 alone or in combination with durvalumab eliminates all detectable NSCLC.
  • Whether treatment with LN-145 alone or in combination with durvalumab extends the life of a patient without their cancer worsening.

LN-145 is an investigational therapy that is being tested in clinical studies and has not been approved by the FDA or any other agency for any indication. A clinical trial is designed to explore efficacy and safety of experimental therapies.  You should talk to your doctor about the benefits and risks of participating in this trial.



  • You have been diagnosed with locally advanced or metastatic NSCLC
  • Your cancer progressed during or following previous therapy
  • You have NOT received prior PD-1 or PD-L1 targeted therapy
  • You are at least 18 years old


If you satisfy these key eligibility criteria, you may be eligible to participate in this clinical trial.  There are other additional eligibility criteria that can only be assessed by a trial physician.

To talk with somebody and to learn more about the trial, please call: 1-866-565-4410

Further details for healthcare providers can be accessed below:

Trial Sites Currently Enrolling Patients

City State Institution
Morristown New Jersey Atlantic Health
Louisville Kentucky University of Louisville
Pittsburgh Pennsylvania UPMC
Portland Oregon Providence Cancer Center
Detroit Michigan Karmanos
Nashville Tennessee Vanderbilt
Los Angeles California UCLA
Seattle Washington University of Washington

1 Rosenberg, S.A., et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell TransferImmunotherapy. Clinical Cancer Research, 17(13), 4550-4557.

2 Goff, S.L. et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Journal of Clinical Oncology, 2016; 34(20), 2389-2397.

3 Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171(1):1-5.

4 Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87(2):365-71; discussion 71-2.

5 Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 2000;27(1):27-35.

6 Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med. 2002;140(5):320-8.

7 Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410-7.

8 Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103.

9 Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107(3).

10 Reynders K, De Ruysscher D. Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. J Thorac Dis. 2016;8(8):E833-5.